2008 - Review: Combination therapy with renin-angiotensin inhibitors reduces proteinuria more than single drugs alone in renal disease

Kohn, Orly
June 2008
ACP Journal Club;6/20/2008, Vol. 148 Issue 4, p7
Academic Journal
The article discusses whether angiotensin-receptor blockers (ARBs) reduce proteinuria more than placebo, other antihypertensive drugs, or their combinations, in patients with renal disease. Research compared ARBs with placebo, angiotensin-converting enzyme inhibitors (ACE-Is), or other antihypertensive drugs in patients with renal disease and microalbuminuria or proteinuria. It is concluded that ARBs and ACE-Is do not differ for reducing proteinuria.


Related Articles

  • Evolution of chronic hypertensive nephropathies treated with ACE inhibitors on patients in pre-dialysis stage. Costea, Andreea-Cristina; Costea, DO; David, Cristiana; Grasa, CN // Journal of Medicine & Life;Apr-Jun2010, Vol. 3 Issue 2, p144 

    Arterial hypertension (HT), being the main factor of negative evolution for chronic nephropathies, has imposed a careful adjustment of pharmacological treatment. The widespread use of angiotensin conversion enzyme inhibitors (ACE inhibitors) has brought into attention the side effects of this...

  • Meeting Reporter. Saunders, Carol S. // Patient Care;8/15/2001, Vol. 35 Issue 15, p16 

    Discusses studies presented at the American Society of Hypertension's 16th Annual Scientific Meeting in San Francisco, California in May 2001. Effectiveness of angiotensin-receptor blockers in reducing the progression of renal disease in patients with diabetes and hypertension; Benefit of...

  • Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study). Peters, Christian Daugaard; Kjaergaard, Krista Dybtved; Jensen, Jens Dam; Christensen, Kent Lodberg; Strandhave, Charlotte; Tietze, Ida Noerager; Novosel, Marija Kristina; Bibby, Bo Martin; Jespersen, Bente // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Background and Aim: Little is known about the tolerability of antihypertensive drugs during hemodialysis treatment. The present study evaluated the use of the angiotensin II receptor blocker (ARB) irbesartan. Design: Randomized, double-blind, placebo-controlled, one-year intervention trial....

  • Combination ACE inhibitor and angiotensin receptor blocker therapy was better than monotherapy in non-diabetic renal disease. Nakao, N.; Yoshimura, A.; Morita, H. // Evidence Based Medicine;Sep2003, p143 

    The article presents a study that investigates the effectiveness of combined angiotensin converting enzyme (ACE) inhibitor and angiotensin receptor blocker treatment in patients with non-diabetic renal disease. It describes the method of the study that observes 301 patients with non-diabetic...

  • COMMENTARY. Kohn, Orly // Evidence Based Medicine;Jun2008, Vol. 13 Issue 3, p73 

    The article comments on the paper by R. Kunz and colleagues on the effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. According to the author, the meta-analysis shows that angiotensin receptor blockers (ARBs) are...

  • Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers. Quednow, Boris B; Kometer, Michael; Geyer, Mark A; Vollenweider, Franz X // Neuropsychopharmacology;Feb2012, Vol. 37 Issue 3, p630 

    The serotonin-2A receptor (5-HT2AR) has been implicated in the pathogenesis of schizophrenia and related inhibitory gating and behavioral inhibition deficits of schizophrenia patients. The hallucinogen psilocybin disrupts automatic forms of sensorimotor gating and response inhibition in humans,...

  • Telmisartan: BIBR 277, Micardis[sup ®] , Pritor[sup ®].  // Drugs in R&D;2002, Vol. 3 Issue 4, p250 

    Adis CommentsTelmisartan [BIBR 277, Micardis, Pritor] is an orally effective non-peptide angiotensin II (AT[sub 1]) antagonist being developed as an antihypertensive. This profile has been selected from R&D Insightâ„¢, a pharmaceutical intelligence database produced by Adis International...

  • Chapter 18. Antihypertensive therapy.  // Clinical & Experimental Nephrology;Jun2009, Vol. 13 Issue 3, p231 

    This article focuses on issues concerning antihypertensive therapy in chronic kidney disease (CKD). It is observed that hypertension is a potent risk factor for cardiovascular disease (CVD), so that antihypertensive therapy contributes directly to cardiovascular disease (CVD) development as well...

  • Review: combination therapy with renin angiotensin inhibitors reduces proteinuria more than single drugs alone in renal disease. Kunz, R. // Evidence Based Medicine;Jun2008, Vol. 13 Issue 3, p73 

    QUESTION In patients with renal disease, do angiotensin receptor blockers (ARBs) reduce proteinuria more than placebo, other antihypertensive drugs, and their combinations? REVIEW SCOPE Studies selected compared ARBs with placebo, ACE inhibitors, or other antihypertensive drugs in patients with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics